VEGFA and urogenital neoplasm: VEGF signaling is considered a canonical angiogenesis promoter for multiple tumors whereby targeting VEGF has been established broadly in the treatment landscape of oncology from other gastrointestinal cancers such as colorectal and hepatocellular carcinoma to genitourinary cancers such as renal cell carcinoma where combination of anti-VEGF therapies with immunotherapy are foundational treatments.